Krzysztof Dynowski

No ORCID on file · 4 papers in corpus · active 2022-2025

Study types

  • article 4

Condition tags

  • endometriosis 4
  • dysmenorrhea 2
  • mesh:D004715 2
  • mesh:D017699 2
  • mesh:D004412 1
article 2025
Safety and efficacy of subcutaneous injection with HMI-115 versus placebo in endometriosis-associated pain in premenopausal women: a multicentre, double-blind, randomised, proof-of-concept phase 2 trial
·doi:10.1016/j.lanogw.2025.100032
article 2024
P-308 Relugolix combination therapy vs relugolix monotherapy with transition to relugolix combination therapy for the treatment of endometriosis-associated pain: implications for cumulative benefit/risk profile
·doi:10.1093/humrep/deae108.273

Abstract Study question How does the benefit/risk profile compare in women with endometriosis-associated pain who initiated relugolix combination therapy (Relugolix-CT) vs relugolix monotherapy with transition to Relugolix-CT? Summary answe…

article 2023
A Plain Language Summary to Learn About Relugolix Combination Therapy for the Treatment of Pain Associated with Endometriosis
Pain management ·doi:10.2217/pmt-2023-0052

WHAT IS THIS SUMMARY ABOUT?: This is a summary of research studies (known as clinical trials) called SPIRIT 1 and SPIRIT 2. The SPIRIT 1 and SPIRIT 2 studies compared how well a medicine called relugolix combination therapy worked in reliev…

article 2022
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)
Lancet (London, England) ·doi:10.1016/s0140-6736(22)00622-5

BACKGROUND: Endometriosis is a common cause of pelvic pain in women, for which current treatment options are suboptimal. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, combined with estradiol and a progestin, was eva…